NCT03159390 (OCERA OP) is a NA clinical trial of phenylacetate salt of ornithine in Healthy, sponsored by Texas A&M University.

Who is sponsoring NCT03159390?

NCT03159390 is sponsored by Texas A&M University.

What drugs are being tested in NCT03159390?

Interventions in NCT03159390: phenylacetate salt of ornithine.

Is NCT03159390 still recruiting?

NCT03159390 is currently completed. Last updated 30 September 2025.

Last reviewed 2025-09-30 · How we verify

NCT03159390: OCERA OP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metabolism of Ornithine Phenylacetate

Completed NA Last updated 30 September 2025

What this trial tests

NA trial testing phenylacetate salt of ornithine in Healthy in 20 participants. Completed in 30 April 2015.

Timeline

3 February 2015

Primary endpoint
30 April 2015

30 April 2015

Quick facts

Lead sponsor	Texas A&M University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	20
Start date	3 February 2015
Primary completion	30 April 2015
Estimated completion	30 April 2015
Sites	1 location across United States

Drugs / interventions tested

phenylacetate salt of ornithine

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Texas A&M University

Who can join

Adults 40 to 70, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intravenous infusion of stable tracers of ornithine, glutamine, glutamate, and glycine will be performed, and collect blood samples, urine samples, and muscle biopsies to evaluate the effect of a continuous oral intake of phenylacetate salt of ornithine (OP) on its metabolic fate.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Abdominal obesity in COPD is associated with specific metabolic and functional phenotypes.
Cruthirds CL, Deutz NEP, Mizubuti YGG, Harrykissoon RI, et al · · 2022 · cited 11× · PMID 36457012 · DOI 10.1186/s12986-022-00714-z
Whole-body and intracellular arginine metabolism in hypertension: role of disease severity and sex.
Hüttl VN, Deutz N, Wierzchowska-McNew RA, Ruebush LE, et al · · 2026 · PMID 42149813 · DOI 10.1093/ajh/hpag047

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Texas A&M University trials

Trials by the same sponsor.

NCT07079995 — Healthy School Recognized Campus: A Hybrid Type 2 Implementation-Effectiveness Trial · NA · recruiting
NCT06950775 — The Neighborhood & Health Study · recruiting
NCT06890689 — Effectiveness of Scaling and Root Planing in Deeper Pockets · active not recruiting
NCT06797089 — Does myTAP Oral Appliance Therapy Including a Mouth Shield Lessen Periodontitis in Mouth-Breathers Who Snore? · NA · completed
NCT05959434 — Integration of Cognitive Processing Therapy and Relapse Prevention for Alcohol Use Disorder and PTSD · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03159390 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Texas A&M University
Last refreshed: 30 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03159390.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing